Selling the PRV, if we get it, will be necessary if the right deal does not materialise and management decides to take paxalisib all the way to market. This part is expensive. However, the business model is not supposed to do this part.
Ann: Kazia Annual Report to shareholders, page-16
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)